Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Verquvo (vericiguat) is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or the need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Vericiguat reduced the risk of cardiovascular death and heart failure (HF) hospitalization in patients with reduced ejection fraction (HFrEF) but showed no significant effect in patients with preserved ejection fraction (HFpEF).
• The primary endpoint, a composite of cardiovascular mortality and first HF-related hospitalization, was significantly reduced by vericiguat, particularly in chronic heart failure patients, with no significant impact on all-cause or cardiovascular mortality.
• Vericiguat's effectiveness was consistent irrespective of atrial fibrillation status and in patients with NT-proBNP levels up to 8000 pg/ml, demonstrating a reduction in both cardiovascular death and HF hospitalizations.
• General Safety Profile: Vericiguat demonstrated a favorable safety profile, with no significant difference in adverse effects compared to placebo. Notable adverse events included hypotension, syncope, and anemia, but these were not statistically significant.
• Significant Safety Concerns: There was a potential, but not statistically significant, increase in the risk of symptomatic hypotension and syncope, particularly in patients with reduced ejection fraction.